KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Exicure’s CEO describes unique SNA™ technology now in clinical trials

Dr. David Giljohann, CEO of Exicure, outlines the company’s unique spherical nucleic acid (SNA™) technology and how this three-dimensional arrangement of nucleic acid will solve the delivery challenge to get into cells and tissues. The biotech company is using digital drug design to use DNA and RNA sequences to create medicines that go after the underlying causes of genetic disease. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology.'


Join our newsletter!